- Home
- LE vs CTNM Comparison
LE vs CTNM Comparison
Compare LE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- CTNM
- Stock Information
- Founded
- LE 1963
- CTNM 2009
- Country
- LE United States
- CTNM United States
- Employees
- LE N/A
- CTNM N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- CTNM
- Sector
- LE Consumer Discretionary
- CTNM
- Exchange
- LE Nasdaq
- CTNM Nasdaq
- Market Cap
- LE 511.4M
- CTNM 453.0M
- IPO Year
- LE N/A
- CTNM 2024
- Fundamental
- Price
- LE $15.33
- CTNM $14.18
- Analyst Decision
- LE Strong Buy
- CTNM Strong Buy
- Analyst Count
- LE 2
- CTNM 4
- Target Price
- LE $20.00
- CTNM $29.25
- AVG Volume (30 Days)
- LE 117.2K
- CTNM 81.0K
- Earning Date
- LE 12-05-2024
- CTNM 11-06-2024
- Dividend Yield
- LE N/A
- CTNM N/A
- EPS Growth
- LE N/A
- CTNM N/A
- EPS
- LE N/A
- CTNM N/A
- Revenue
- LE $1,442,231,000.00
- CTNM N/A
- Revenue This Year
- LE N/A
- CTNM N/A
- Revenue Next Year
- LE $2.01
- CTNM N/A
- P/E Ratio
- LE N/A
- CTNM N/A
- Revenue Growth
- LE N/A
- CTNM N/A
- 52 Week Low
- LE $6.35
- CTNM $12.33
- 52 Week High
- LE $19.88
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- LE 43.00
- CTNM N/A
- Support Level
- LE $14.46
- CTNM N/A
- Resistance Level
- LE $17.29
- CTNM N/A
- Average True Range (ATR)
- LE 0.69
- CTNM 0.00
- MACD
- LE -0.14
- CTNM 0.00
- Stochastic Oscillator
- LE 27.88
- CTNM 0.00
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.